Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12713MR)

This product GTTS-WQ12713MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12713MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5441MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDA 1
GTTS-WQ1833MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ3964MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ2453MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ7835MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ1450MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACC-001
GTTS-WQ7827MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ14603MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW